原发性肺癌罕见靶点靶向治疗中国临床诊疗指南(2024版)
Clinical guidelines for targeted therapy of rare variants in primary lung cancer in China(2024 edition)
中国医师协会肿瘤多学科诊疗专业委员会 国家肿瘤质控中心肺癌质控专家委员会 王洁 1赫捷2
作者信息
- 1. 国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院内科,北京 100021
- 2. 国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院胸外科,北京 100021
- 折叠
摘要
目前,肺癌在中国恶性肿瘤中的发病率和死亡率均居首位.驱动基因突变的发现为精准医学提供了有力的治疗手段,靶向治疗已成为肺癌诊疗指南中的重要部分,越来越多的罕见突变靶向药物有效改善了肺癌患者的生存.根据世界卫生组织指南制定手册的原则和方法,中国医师协会肿瘤多学科诊疗专业委员会和国家肿瘤质控中心肺癌质控专家委员会在整合罕见靶点检测方法、治疗药物临床研究新进展,并结合国内外诊疗指南及中国实际国情和临床实践的基础上,制定原发性肺癌罕见靶点靶向治疗中国临床诊疗指南,旨在指导中国肺癌罕见靶点诊疗临床实践,完善规范化诊疗体系,提高中国肺癌诊疗水平.
Abstract
Currently,lung cancer ranks first in both incidence and mortality rate among malignancies in China.The discovery of oncogenic driver mutations provides a powerful strategy for precision medicine.Targeted therapies have become an essential treatment in guidelines worldwide.Emerging rare variants-targeted drugs improve patient survival effectively.Following the World Health Organization's Handbook for Guidelines Development,this guide integrates rare variants detection assay and new progress in clinical research on therapeutic drugs,combines domestic and foreign diagnosis and treatment guidelines with China's national conditions and clinical practices,and formulates the guideline for the clinical diagnosis and treatment of primary lung cancer targeted therapy for rare variants in China.This guideline aims to standardize the clinical practice of rare variants diagnosis and treatment of lung cancer,improve the standardized diagnosis and treatment system,and improve the level of lung cancer diagnosis and treatment in China.
关键词
肺肿瘤/罕见突变/靶向治疗/指南Key words
Lung neoplasms/Rare variants/Targeted therapy/Guideline引用本文复制引用
出版年
2024
NETL
NSTL
万方数据